Study of G-CSF in advanced lung adenocarcinoma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how a drug called G-CSF affects certain immune cells (MDSCs) and cancer stem cells in people with a specific type of advanced lung cancer (adenocarcinoma). It may help doctors understand how to make current treatments work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lung cancer called adenocarcinoma that has spread or is locally advanced and cannot be treated with local therapy.
- You must be receiving chemotherapy and immunotherapy as your first treatment for this cancer.
- You must not have a small cell lung cancer.
- You must not have a targetable genetic change in the EGFR, ALK, or ROS1 genes.
- You must not be taking high doses of steroids (more than 10 mg per day) or have an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial compares giving a medication called G-CSF (which helps your body make white blood cells to fight infection) early versus later after chemotherapy. The goal is to see which timing works best to prevent infections for people with non-Hodgkin's lymphoma.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.